TrialsgrambetaRCTs are beautiful

VICTORIA

2020

Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction

In 5,050 patients with worsening HFrEF (EF < 45%), vericiguat reduced cardiovascular death or first heart-failure hospitalisation compared with placebo.

Result

Efficacy: Composite of death from cardiovascular causes or first hospitalisation for heart failureHR 0.90 (95% CI 0.82-0.98) · P = 0.02

Below 1 favours vericiguat, above 1 favours placebo.

Event rates
Absolute difference
3.0 points
NNT
34

Absolute difference and NNT are derived from the event rates.

Also reported: Over median 10.8 months.

Original publication
Subtopic
sGC stimulator
Design
Double-blind placebo-controlled RCT, phase 3
Relevance
Supporting: context rather than must-know.
Source
Armstrong PW, et al. N Engl J Med. 2020;382(20):1883-1893.doi 10.1056/NEJMoa1915928

Discussion & critique

Modest relative benefit in a very high-risk, recently decompensated cohort, with no reduction in CV death alone. Added an oral soluble guanylate cyclase stimulator as an option for worsening HFrEF.

Discussed in podcasts